IFP Advisors’s Century Therapeutics IPSC Stock Holding History

IFP Advisors’s Portfolio IPSC Stock Details IPSC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-6	Closed	-$3	–	4965
2025 Q3	$3	Hold	6	–	–	﹤0.01%	4819
2025 Q2	$3	Buy	+6	New	+$3	﹤0.01%	4894

Other funds holding IPSC

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

SSC

Spruce Street Capital New York $416M AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

IFP Advisors's IPSC Position: Q4 2025 in Review

IFP Advisors sold out of Century Therapeutics (IPSC) in Q4 2025, closing a stake of 6 shares — an estimated $3 sold.

IFP Advisors first reported a position in IPSC in Q2 2025 and held it in 2 quarters. The position peaked at $3 in Q3 2025. 47 funds tracked by Wall St. Rank hold IPSC as of Q4 2025.

IFP Advisors reported no remaining Century Therapeutics position as of Q4 2025 after selling out during the quarter.
IFP Advisors sold 6 Century Therapeutics shares in Q4 2025, an estimated $3.
IFP Advisors first reported a position in Century Therapeutics in Q2 2025 and held it in 2 quarters.
IFP Advisors's Century Therapeutics position peaked at $3 in Q3 2025.
47 funds tracked by Wall St. Rank held Century Therapeutics as of Q4 2025.

Based on IFP Advisors's 13F filing for Q4 2025, filed 6 Feb 2026.